α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease-Reference-Cited by-同舟云学术

α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease

Published:2018-06-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Ludtmann Marthe H. R.,Angelova Plamena R.,Horrocks Mathew H.,Choi Minee L.,Rodrigues Margarida,Baev Artyom Y.,Berezhnov Alexey V.,Yao Zhi,Little Daniel,Banushi Blerida,Al-Menhali Afnan Saleh,Ranasinghe Rohan T.,Whiten Daniel R.,Yapom Ratsuda,Dolt Karamjit Singh,Devine Michael J.^ORCID,Gissen Paul^ORCID,Kunath Tilo^ORCID,Jaganjac Morana,Pavlov Evgeny V.,Klenerman David,Abramov Andrey Y.,Gandhi Sonia

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-04422-2.pdf

Reference63 articles.

1. Kruger, R. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108 (1998).

2. Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047 (1997).

3. Chartier-Harlin, M. C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 1167–1169 (2004).

4. Singleton, A. B. et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302, 841 (2003).

5. Mor, D. E. et al. Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20, 1560–1568 (2017).

Cited by 377 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis in Parkinson's disease —— The iron-related degenerative disease;Ageing Research Reviews;2024-11

2. AAV-aMTD-Parkin, a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson's and Alzheimer’s diseases;Pharmacological Research;2024-10

3. Synthesis and pharmacological evaluation of novel N-aryl-cinnamoyl-hydrazone hybrids designed as neuroprotective agents for the treatment of Parkinson’s disease;Bioorganic Chemistry;2024-09

4. Curcumin as a potential therapeutic agent for treating neurodegenerative diseases;Neurochemistry International;2024-09

5. Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions;Neuron;2024-09